(uh-KA-luh-BROO-tih-nib)
This page contains brief information about acalabrutinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Acalabrutinib is approved to treat:
- Chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.
- Mantle cell lymphoma in adults who have received at least one other type of treatment.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that acalabrutinib provides a clinical benefit in these patients.
Acalabrutinib is also being studied in the treatment of other types of cancer.
More About Acalabrutinib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Acalabrutinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Acalabrutinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
